Philip C. Prorok

17.0k total citations · 1 hit paper
133 papers, 6.6k citations indexed

About

Philip C. Prorok is a scholar working on Oncology, Pulmonary and Respiratory Medicine and Statistics and Probability. According to data from OpenAlex, Philip C. Prorok has authored 133 papers receiving a total of 6.6k indexed citations (citations by other indexed papers that have themselves been cited), including 75 papers in Oncology, 42 papers in Pulmonary and Respiratory Medicine and 23 papers in Statistics and Probability. Recurrent topics in Philip C. Prorok's work include Colorectal Cancer Screening and Detection (59 papers), Global Cancer Incidence and Screening (33 papers) and Statistical Methods in Clinical Trials (18 papers). Philip C. Prorok is often cited by papers focused on Colorectal Cancer Screening and Detection (59 papers), Global Cancer Incidence and Screening (33 papers) and Statistical Methods in Clinical Trials (18 papers). Philip C. Prorok collaborates with scholars based in United States, Canada and Malaysia. Philip C. Prorok's co-authors include John K. Gohagan, Paul F. Pinsky, Barnett S. Kramer, Richard B. Hayes, Barnett S. Kramer, Richard M. Fagerstrom, H. Gilbert Welch, A. James O’Malley, Timothy R. Church and Pamela M. Marcus and has published in prestigious journals such as New England Journal of Medicine, The Lancet and JAMA.

In The Last Decade

Philip C. Prorok

130 papers receiving 6.3k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Breast-Cancer Tumor Size, Overdiagnosis, and Mammography Screening Effectiveness

2016 458 citations Philip C. Prorok, Barnett S. Kramer et al. profile →

Peers

Countries citing papers authored by Philip C. Prorok

Since Specialization

Citations

This map shows the geographic impact of Philip C. Prorok's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Philip C. Prorok with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Philip C. Prorok more than expected).

Fields of papers citing papers by Philip C. Prorok

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Philip C. Prorok. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Philip C. Prorok. The network helps show where Philip C. Prorok may publish in the future.

Co-authorship network of co-authors of Philip C. Prorok

This figure shows the co-authorship network connecting the top 25 collaborators of Philip C. Prorok. A scholar is included among the top collaborators of Philip C. Prorok based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Philip C. Prorok. Philip C. Prorok is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Framework to Select Multi-Cancer Detection Assays in the National Cancer Institute’s Vanguard Study 2025 ·Cancer Epidemiology Biomarkers & Prevention ·(unknown), Amanda L. Skarlupka, Christos Patriotis, Wendy S. Rubinstein, Paul F. Pinsky, Wade E. Bolton, Anthony Dickherber, David B. Edelman, Lyndsay N. Harris, Hormuzd A. Katki, Erin Lavik, (unknown), (unknown), Philip C. Prorok, David F. Ransohoff, Sarah M. Temkin, Lori M. Minasian	0
2	Randomized Study of Metformin and Intensive Lifestyle Intervention on Cancer Incidence over 21 Years of Follow-up in the Diabetes Prevention Program 2025 ·Cancer Prevention Research ·Brandy M. Heckman‐Stoddard, Jill P. Crandall, Sharon L. Edelstein, Philip C. Prorok, Dana Dabelea, Richard F. Hamman, Helen P. Hazuda, Edward S. Horton, Mary A. Hoskin, Marjorie Perloff, (unknown), William C. Knowler, Leslie G. Ford, Marinella Temprosa	3
3	Cohort Profile: The Prostate, Lung, Colorectal and Ovarian (PLCO) Cancer Screening Trial 2025 ·International Journal of Epidemiology ·Eric A. Miller, Claire S. Zhu, Neeraj K. Saxena, Philip C. Prorok, Wen‐Yi Huang, Steven C. Moore, Amanda Black, Jerome Mabie, Tom Riley, Michael Young, Paul F. Pinsky	0
4	Cancer screening with multicancer detection tests: A translational science review 2024 ·CA A Cancer Journal for Clinicians ·Wendy S. Rubinstein, Christos Patriotis, Anthony Dickherber, Paul K. J. Han, Hormuzd A. Katki, (unknown), Paul F. Pinsky, Philip C. Prorok, Amanda L. Skarlupka, Sarah M. Temkin, Philip E. Castle, Lori M. Minasian	34
5	Study design considerations for trials to evaluate multicancer early detection assays for clinical utility 2022 ·JNCI Journal of the National Cancer Institute ·Lori M. Minasian, Paul F. Pinsky, Hormuzd A. Katki, Anthony Dickherber, Paul K. J. Han, Lyndsay N. Harris, Christos Patriotis, Sudhir Srivastava, Carol J. Weil, Philip C. Prorok, Philip E. Castle	36
6	Effect of flexible sigmoidoscopy screening on colorectal cancer incidence and mortality: long-term follow-up of the randomised US PLCO cancer screening trial 2018 ·The Lancet. Gastroenterology & hepatology ·Eric A. Miller, Paul F. Pinsky, Robert E. Schoen, Philip C. Prorok, Timothy R. Church	73
7	Data sharing in clinical trials: An experience with two large cancer screening trials 2017 ·PLoS Medicine ·Claire S. Zhu, Paul F. Pinsky, James E. Moler, (unknown), Jerome Mabie, Joshua M. Rathmell, Tom Riley, Philip C. Prorok, Christine D. Berg	6
8	Active follow-up versus passive linkage with cancer registries for case ascertainment in a cohort 2016 ·Cancer Epidemiology ·Paul F. Pinsky, Kai Yu, Amanda Black, Wen‐Yi Huang, Philip C. Prorok	12
9	Extended mortality results for ovarian cancer screening in the PLCO trial with median 15 years follow-up 2016 ·Gynecologic Oncology ·Paul F. Pinsky, Kelly J. Yu, Barnett S. Kramer, Amanda Black, Saundra S. Buys, Edward E. Partridge, John K. Gohagan, Christine D. Berg, Philip C. Prorok	101
10	Conceptualizing Overdiagnosis in Cancer Screening 2015 ·JNCI Journal of the National Cancer Institute ·P. M. Marcus, Philip C. Prorok, Andrea Miller, Emily DeVoto, Barnett S. Kramer	59
11	Occurrence of Distal Colorectal Neoplasia Among Whites and Blacks Following Negative Flexible Sigmoidoscopy: An Analysis of PLCO Trial 2015 ·Journal of General Internal Medicine ·Adeyinka O. Laiyemo, Chyke A. Doubeni, Paul F. Pinsky, V. Paul Doria‐Rose, Robert S. Bresalier, Thomas Hickey, Thomas Riley, Timothy R. Church, Joel L. Weissfeld, Robert E. Schoen, Pamela M. Marcus, Philip C. Prorok	6
12	Assessing the Risk of Ovarian Malignancy in Asymptomatic Women With Abnormal CA 125 and Transvaginal Ultrasound Scans in the Prostate, Lung, Colorectal, and Ovarian Screening Trial 2013 ·Obstetrics and Gynecology ·Edward E. Partridge, Robert T. Greenlee, Thomas L. Riley, John Commins, Lawrence R. Ragard, (unknown), Saundra S. Buys, Philip C. Prorok, Mona N. Fouad	21
13	Factors associated with inadequate colorectal cancer screening with flexible sigmoidoscopy 2011 ·Cancer Epidemiology ·Adeyinka O. Laiyemo, Chyke A. Doubeni, Paul F. Pinsky, V. Paul Doria‐Rose, Andrew Sanderson, Robert S. Bresalier, Joel L. Weissfeld, Robert E. Schoen, Pamela M. Marcus, Philip C. Prorok, Christine D. Berg	5
14	Lung Cancer Screening in the Randomized Prostate, Lung, Colorectal, and Ovarian (PLCO) Cancer Screening Trial 2010 ·JNCI Journal of the National Cancer Institute ·William G. Hocking, Ping Hu, Martin M. Oken, (unknown), Paul A. Kvale, Philip C. Prorok, Lawrence R. Ragard, John Commins, David A. Lynch, Gerald L. Andriole, Saundra S. Buys, Mona N. Fouad, Carl R. Fuhrman, Claudine Isaacs, Lance Yokochi, Thomas L. Riley, Paul F. Pinsky, John K. Gohagan, Christine D. Berg	71
15	Effect of length biased sampling of unobserved sojourn times on the survival distribution when disease is screen detected 2009 ·Statistics in Medicine ·Karen Kafadar, Philip C. Prorok	10
16	Prediction of True Positive Lung Cancers in Individuals with Abnormal Suspicious Chest Radiographs—A Prostate, Lung, Colorectal, and Ovarian Cancer Screening Trial Study 2009 ·Journal of Thoracic Oncology ·Martin C. Tammemägi, Matthew T. Freedman, Paul F. Pinsky, Martin M. Oken, Ping Hu, Thomas L. Riley, Lawrence R. Ragard, Christine D. Berg, Philip C. Prorok	25
17	Computational methods in medical decision making: to screen or not to screen? 2005 ·Statistics in Medicine ·Karen Kafadar, Philip C. Prorok	6
18	Development Tracks for Cancer Prevention Markers 2004 ·Disease Markers ·Stuart G. Baker, Barnett S. Kramer, Philip C. Prorok	8
19	The Lung Screening Study: The National Cancer Institute's Randomized Feasibility Study of Spiral CT versus Chest X-ray in Lung Cancer Screenin 2003 ·CHEST Journal ·Paul A. Kvale, John K. Gohagan, Pamela M. Marcus, Richard M. Fagerstrom, Paul F. Pinsky, Barnett S. Kramer, Philip C. Prorok	3
20	Lung Cancer Mortality in the Mayo Lung Project: Impact of Extended Follow-up 2000 ·JNCI Journal of the National Cancer Institute ·P. M. Marcus, Erik J. Bergstralh, Richard M. Fagerstrom, Duane E. Williams, R Fontana, William F. Taylor, Philip C. Prorok	361

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact